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Abstract
Background: Engineered nanomaterials (ENMs) interact with different biomolecules as soon as they are in contact,
resulting in the formation of a biomolecule ‘corona’. Hence, the ‘corona’ defines the biological identity of the ENMs
and could affect the response of the immune system to ENM exposure. With up to 40 % of the world population
suffering from type I allergy, a possible modulation of allergen effects by binding to ENMs is highly relevant with
respect to work place and consumer safety. Therefore, the aim of this present study was to gain an insight into the
interactions of gold nanoparticles with different seasonally and perennially occurring outdoor and indoor allergens.
Methods: Gold nanoparticles (AuNPs) were conjugated with the major allergens of birch pollen (Bet v 1), timothy
grass pollen (Phl p 5) and house dust mite (Der p 1). The AuNP-allergen conjugates were characterized by means of
TEM negative staining, dynamic light scattering (DLS), z-potential measurements and hyperspectral imaging.
Furthermore, 3D models were constructed, based on the characterization data, to visualize the interaction between
the allergens and the AuNPs surface. Differences in the activation of human basophil cells derived from birch/grass
pollen- and house dust mite-allergic patients in response to free allergen and AuNP-allergen conjugates were determined
using the basophil activation assay (BAT). Potential allergen corona replacement during BAT was controlled for
using Western blotting. The protease activity of AuNP-Der p 1 conjugates compared to free Der p 1 was assessed, by
an enzymatic activity assay and a cellular assay pertaining to lung type II alveolar epithelial cell tight junction integrity.
Results: The formation of a stable corona was found for all three allergens used. Our data suggest, that depending on
the allergen, different effects are observed after binding to ENMs, including enhanced allergic responses
against Der p 1 and also, for some patients, against Bet v 1. Moreover elevated protease activity of AuNP-Der
p 1 conjugates compared to free Der p 1 was found.
Conclusion: In summary, this study presents that conjugation of allergens to ENMs can modulate the human allergic
response, and that protease activity can be increased.
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Background
With the increasing use of ENMs concerns about the
safety upon exposure of workers, consumers and the en-
vironment were raised [1–3]. One crucial feature of
ENMs is that they possess a higher free energy than the
bulk material, which means that the ENMs surface will
interact with different biomolecules as soon as they are
in contact, resulting in the formation of a ‘corona’
around the ENMs [4]. The biomolecule corona changes
the extrinsic properties of the ENMs, but also structures
and functions of the biomolecules themselves may be
modified upon binding. Thus, if the corona consists of
an allergen the overall bio-reactivity of the ENM/corona
complex may have the potential to elicit or modulate an
allergic response [5–8].
As the overall size of the ENMs would increase only
marginally by allergen binding, the ENMs-allergen con-
jugates could still be inhaled and could translocate from
the lung into the bloodstream. Contact with epithelial
and/or immune cells and in particular uptake into these
cells may result in immune responses [9, 10]. Type I
allergy, affecting 30–40 % of the population worldwide,
is characterized by the production of immunoglobulin E
(IgE) antibodies against allergens. IgE-mediated allergic
rhinitis is a risk factor for asthma, a life-long chronic
inflammatory disease of the airways, which seriously im-
pacts quality of life and can, when uncontrolled, lead to
death [11]. Upon allergic sensitization in the human air-
ways, epithelial cells encountering allergens can release
thymic stromal lymphopoietin (TSLP) to attract, activate
and polarize dendritic cells (DCs). Activated DCs mi-
grate to lymph nodes, expressing the CC-chemokine li-
gands (CCL) 17 and CCL22 for T cell attraction [12–14].
In the lymph node, DCs present processed antigens to T
cells, and by several mechanisms initiate an immune de-
viation into a T helper cell 2 (TH2)-type profile charac-
terized by secretion of interleukin (IL)-4, IL-5 and IL-13.
The TH2 cells induce a class-switch in B cells resulting
in the production of allergen-specific IgE [15, 16]. Dur-
ing the acute phase of allergy (effector phase), IgE mole-
cules on mast cells and basophils crosslink the cells’
high affinity IgE receptors, initiating a signaling cascade
that leads to the release of preformed mediators, en-
zymes and cytokines, resulting in pathological damage
and clinical manifestation of allergy [17–19]. Allergic
symptoms can occur seasonally, e.g. after exposure to
pollen, or perennially during the exposure to indoor al-
lergens [20]. In Europe the most allergenic tree pollen is
produced by birch (major allergen Bet v 1). Pollinosis is
also caused by grass pollen, a well-known example being
timothy grass (major allergens Phl p 1 and 5) [21].
House dust mite, found in 48 % of European homes,
represents the major perennial indoor allergen source
(major allergens Der p 1 and 2) [22, 23]. Research on
co-exposure to allergens and particles has initially fo-
cused on diesel exhaust particles (DEPs). It was shown
in previous studies that DEPs can bind Lol p 1, a major
grass pollen allergen, and that DEPs can increase the
production of allergen-specific IgE in Epstein-Barr virus
(EBV)-transformed human B-lymphocytes when exposed
to different polycyclic aromatic hydrocarbons (PAHs), a
main component found in DEPs [24, 25]. When DEPs
and different allergens were administered simultaneously,
higher specific IgE levels were found in human nasal
lavages as well as in blood drawn from mice [24, 26, 27].
Much less is known about effects of co-exposure of aller-
gens with ENMs. Numerous studies have explored options
to employ ENMs as carriers in immunotherapy against
allergies [28–32], but the possible risk of unintentional co-
exposure has been less explored. The studies performed
so far have mainly focused on various established mouse
models [33–39].
Furthermore, upon release of ENMs into the environ-
ment, which can occur by accident but also upon dis-
posal or via abrasion, ENMs can interact with different
allergens. Therefore, this study aimed to determine effects
of allergens present as corona compounds on ENMs on the
allergic response of human cells, focusing on basophils and
on alveolar epithelial cells. Bet v 1 for tree and Phl p 5 for
grass pollen, both representing outdoor allergens, and Der
p 1, the major allergen for house dust mite, representing in-
door allergens were selected. The binding of allergens onto
AuNPs and investigated differences in the allergic response
of free compared to conjugated allergens was determined.
AuNPs were chosen as model ENMs as their reactivity is
low, allowing well controlled characterization, and they do
not cause an allergic response on their own, enabling an
investigation solely on modulation of allergen-specific re-
sponses upon particle binding. Furthermore, the behavior
of these ENM-allergen conjugates may provide insights into
the use of AuNPs as candidates in nanotherapeutic
applications. Additionally, as the enzymatic function of
Der p 1 as a cysteine protease is considered to play a role
in the allergic sensitization, we also investigated the
influence of the AuNP-allergen interaction on proteolytic
activity of Der p 1 [12, 40].
Methods
AuNP-allergen conjugates
AuNPs (3.5*1010 NPs/ml, 50 nm, stabilized in 0.1 mM
phosphate buffered-saline (PBS), Sigma-Aldrich, St. Louis,
MO, USA) were incubated with different concentrations
of purified recombinant allergens, i.e. 2.5 μg Bet v 1
(courtesy of C. Ackaert as described in 2014 [41]),
5 μg Der p 1 (Indoor Biotechnologies INC., Cardiff,
United Kingdom) or 3 μg Phl p 5 (Allergopharma GmbH,
Reinbek, Germany) as described by O. Cromwell et al.
[42], on a test tube rotator (Snijders, Tilburg, Netherlands)
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at 4 °C overnight. The excess protein was removed by
performing three washing steps of 5 min centrifugation at
18,000 rpm followed by resuspension in the original buffer.
Characterization of AuNPs, AuNP-allergen conjugates and
allergens
AuNPs were characterized by TEM. The protein corona
of AuNP-allergen conjugates was also characterized by
TEM with protein negative staining. For these investiga-
tions samples were taken directly after the conjugation,
before the removal of unbound proteins, and were incu-
bated with 1 % uranyl acetate on coated copper grids to
stain the proteins. Images were taken using a LEO 912
AB Omega transmission electron microscope (Carl Zeiss,
Oberkochen, Germany) operated with a LaB6 cathode at a
voltage of 120 kV. Images were filtered at zero energy loss.
The hydrodynamic radius and surface charge of AuNPs
and AuNP-allergen conjugates were determined using a
Malvern ZetaSizer Nano ZSP (Malvern Instruments,
Malvern, UK). The assessment of the molecular size and
potential protein aggregation of the free allergens was
performed on the DLS802 (Viscotek, Houston, TX, USA)
as previously described by Himly et al. [43].
For further confirmation of hard corona formation,
optical and hyperspectral imaging analysis were con-
ducted on a darkfield-based optical illumination system
from CytoViva (CytoViva Inc., Auburn, AL, USA).
AuNPs and AuNP-allergen conjugates were applied to a
microscope slide and covered with a cover glass (both
Carl Roth GmbH CoKG, Karlsruhe Germany). The
principle of the measurement is based upon the charac-
teristic scattering profile of AuNPs. Each pixel of the
image was recorded at a wavelength of 400–1000 nm,
and was automatically compared by the classification
algorithm spectral angle mapper (SAM) to the AuNP-
allergen conjugates. The data is presented as normalized
mean regions of interest (ROI’s) of 1100 AuNP-allergen
conjugates normalized to the mean ROI of 1100 AuNPs.
Quantification of the bound allergen
Reversed phase - high performance liquid chromatog-
raphy (RP-HPLC) was performed to determine the free
allergen concentrations before and after the conjugation.
Indirect quantification of AuNP-bound allergen was
achieved by comparing the obtained peak areas of the
UV absorption signals at 214 nm of the original free
allergen suspension with the signal obtained from super-
natants collected after conjugation with AuNPs, after
the above-mentioned washing steps. The measurements
were carried out on an UltiMate 3000 system (Thermo-
Fisher Scientific Inc., Palo Alto, CA, USA) using a C18
AcclaimTM 300 column (2.1×150 mm, 3 μm, Thermo-
Fisher) at a flow rate of 500 μl/min and a column
temperature of 50 °C. The gradient of the solvents A
(H2O + 0.1 % trifluoroacetic acid (TFA)) and B (aceto-
nitrile (ACN) + 0.1 % TFA, both Sigma-Aldrich) was
programmed in the following way: 10–60 % solvent A
10 min, 80 % solvent A 5 min, 10 % solvent A 10 min. A
full loop injection of 20 μl with a loop volume of 100 μl
was used.
3D model of AuNP-allergen conjugates
Molecular graphics and analyses were performed with
the UCSF Chimera package [44]. Atomic coordinates of
allergens were obtained from experimentally determined
structures of Bet v 1 (PDB code: 4a88, chain A), Der p 1
(PDB code: 3f5v, chain A) and Phl p 5 (PDB code: 2m64,
chain A, NMR model 1) [45, 46]. All three allergens
were visualized in a monomeric state and positioned
randomly on the surface of an idealized AuNP repre-
sented by a sphere of 51 nm diameter, approximately cor-
responding to the nanoparticle size determined by DLS
(see Table 1). Having to decide for plausible orientations of
the protein molecules on the AuNP surface, we followed
the rationale that the negative potential of a citrate-coated
gold surface may select orientations of the protein mole-
cules where positively charged surface patches face the
AuNP surface. In order to identify such patches, charges
and atom radii were assigned to protein atoms using
PDB2PQR [47, 48] and the PARSE parameter set [49].
Subsequently, electrostatic potentials were calculated
with the APBS software package [50] (129×129×129
grid points, solute dielectric constant = 2.0, solvent di-
electric constant = 78.54, solvent radius = 1.4 Angstrom).
The following coarse-grained docking procedure was ap-
plied to find electrostatically preferred orientations of a
protein molecule relative to the AuNP: for all possible
1×12×12 = 1728 combinations of 30°-rotations about three
orthogonal axes centered at the molecule, we minimized
the distance of the rotated allergen to the AuNP (distance
cutoff = 5 Angstrom) and then summed up the electro-
static potential values at all grid points located at the
AuNP surface. Orientations were ranked by this sum and
top-ranking solutions (i.e. those with the most positive
sum) were chosen for visualization.
Basophil activation test
Whole blood of nine patients allergic to Bet v 1, five pa-
tients allergic to Der p 1 and six patients allergic to Phl
p 5, displaying rhinitis and conjunctivitis symptoms, di-
agnosed at the allergy clinic of the Paracelsus Medical
University of Salzburg were studied. The study was ap-
proved by the local ethics committee and all patients
participating gave their written informed consent. Baso-
phil activation was performed from Ethylene diamine
tetraacetic acid (EDTA)-whole blood using Flow CAST®
(Buehlmann Laboratories, Schoenenbuch, Switzerland)
according to the manufacturer’s protocol. Whole blood
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samples were stimulated with different concentrations of
allergen or AuNP-allergen conjugates (Bet v 1: 50 –
0.048 ng, Der p 1: 50 – 0.04 ng, Phl p 5: 50 – 0.078 ng),
and the corresponding amounts of free allergen were in-
cluded as controls. Processed samples were analyzed by
flow cytometry (FACSCantoTM II, BD Bioscience, San
Jose, CA, USA) using FACSDiva 5.02. Basophils were
gated as side scatter (SSC)low/C-C chemokine receptor 3
(CCR3)high and activated basophils were identified as
Cluster of differentiation (CD) 63high when cut-off was
set with the negative stimulation control. CD63 upregula-
tion was assessed in a minimum of 500 basophils per
assay. C50 values (i.e. allergen concentration inducing
half-maximal basophil activation) for the AuNP-allergen
conjugates were determined by logarithmic approximation
(certainty R2 > 0.900) in comparison to the allergen alone.
Enzymatic activity assay
Different concentrations of free Der p 1 (50 and 100 ng)
and 30 ng AuNP-Der p 1 conjugates were incubated
with 1 mM dithiothreitol (DTT), as reducing agent to
activate the cysteine protease, for 10 min at 37 °C. For
conjugates the given value refers to the amount of
conjugated allergen. After incubation the assay was
conducted in 50 mM sodium phosphate buffer, pH 7.0,
with 100 μM Boc-Gln-Ala-Arg-AMC (PeptaNova GmbH,
Sandhausen, Germany) as substrate according to the
manufacturer’s protocol. The fluorescence intensity was
recorded at ex/em 380/460 nm using a M200Pro
plate reader (Tecan, Groedig, Austria) for 20 min.
Permeability assay and TEER measurements
The human lung alveolar adenocarcinoma cell line A549
(ATCC, Manassas, USA) was cultured in RPMI 1640
medium (Sigma-Aldrich), supplemented with 10 % fetal
calf serum (FCS; PAA, Pasching, Austria), 100 U/ml
Penicillin, 100 μg/ml Streptomycin, 2 mM L-glutamine
(Sigma-Aldrich). The cells were seeded in 24-well inserts
(high pore density, 0.33 cm2 growth area, 0.4 μm PET,
Merck-Millipore KGaA, Darmstadt, Germany) at a dens-
ity of 1.5 × 105 cells/ml. Transepithelial electrical resist-
ance (TEER) measurements were performed using a
TEER electrode (WPI, Sarasotay, USA) to monitor the
cell growth every 24 h. Therefore, the medium was
changed and the electrode was washed with RPMI
medium between measurements. The TEER values were
calculated for the dimension [Ohm*cm2] by subtracting
the medium only control from the obtained values
followed by multiplication with the surface area of the
insert. As soon as no further increase in TEER values
could be observed, the medium was changed to growth
medium without FCS and cells were exposed to 2.5 mM
EDTA as a positive control, 0.01 mM DTT, 3.5 × 1010
AuNPs, 530 ng free Der p 1, and 3.5 × 1010 AuNP-Der p
1 conjugates for 24 h. Thereafter, the medium was changed,
and TEER measurements were performed as previously de-
scribed. For determination of the epithelium permeability
A549 cells were incubated with 2.5 μg/insert of Fluorescein
(Sigma-Aldrich) at 37 °C for 1 h. To assess the percentage
of permeated Fluorescein, 100 μl of the lower compartment
was transferred into black culture plates (Greiner Bio-One
GmbH, Kremsmuenster, Austria) and the fluorescence
at ex/em 485/515 nm was measured using a plate
reader (Tecan).
Statistical analysis
For TEER measurements and permeability experiments,
results are expressed as mean value ± standard deviation
(SD) of 3 independent experiments; calculated using
Microsoft® Office Excel 2007. Statistical analysis was per-
formed using Student’s t-test in GraphPad Prism 5. Due
to the donor-to-donor variations expected and observed
in the BAT measurements, no statistical analysis was
performed for these experiments.
Results and discussion
Preparation and characterization of AuNPs and
AuNP-allergen conjugates
Allergen conjugation was performed using commercially
available citrate-stabilized 50 nm AuNPs (Sigma-Aldrich),
and characterized using TEM, DLS, and zeta potential
determination. AuNPs were determined to have a
negative zeta potential, which was due to the citrate
coating to prevent AuNP aggregation (Table 1), and
Table 1 Size distribution, PDI and zeta potential measurements of AuNPs, allergens and AuNP-allergen conjugates
Sample Average Diameter (nm) PdI Difference from AuNPs (nm) Zeta Potential (mV) Difference from AuNPs (mV)
Au NPs 50.9 ± 0.6 ±0.010 --- - 42.2 ± 2.2 ---
Bet v 1 3.92 ± 0.6 --- --- --- ---
Der p 1 4.94 ± 2.4 --- --- --- ---
Phl p 5 6.48 ± 0.6 --- --- --- ---
AuNP-Bet v 1 53.1 ± 1.3 0.101 ± 0.020 2.2 ± 0.7 - 39.2 ± 0.5 3 ± 1.7
AuNP-Der p 1 54.2 ± 2.8 0.141 ± 0.010 3.3 ± 2.2 - 29.6 ± 1.1 12.6 ± 1.1
AuNP-Phl p 5 54.6 ± 1.7 0.103 ± 0.016 3.6 ± 1.1 - 34.2 ± 0.9 8 ± 1.3
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as depicted in Fig. 1a the TEM images show mono-
dispersed AuNPs of approximately 50 nm, confirmed
in DLS measurements with a low polydispersity index
(PdI) (Fig. 1b). In order to allow the formation of a
stable corona, the AuNPs were conjugated overnight
with highly purified recombinant allergens, either Bet
v 1, Der p 1 or Phl p 5, and the resulting AuNP-aller-
gen conjugates were separated from the excess allergens
by a series of centrifugation and washing steps. After the
conjugation the presence of an intact protein corona on
the AuNP-allergen conjugates was verified using TEM
with negative staining (Fig. 1a), DLS (Fig. 1b), zeta
potential measurements (Table 1), hyperspectral im-
aging (Fig. 1c) and RP-HPLC (Fig. 1d).
The TEM negative staining visualized the bound aller-
gen corona as a light halo around the AuNPs on a dark
protein background, which was found for all three AuNP-
allergen conjugates. Additionally, optical and hyperspec-
tral imaging of the AuNPs and AuNP-allergen conjugates
were performed using the system of Cytoviva. A clear shift
in wavelength upon allergen binding to AuNPs was found
for all three AuNP-allergen conjugates. Results from all
Fig. 1 Characterization of AuNPs and AuNP-allergen conjugates. a TEM imaging and TEM negative staining. b Size distribution by intensity obtained
from DLS measurements. c Hyperspectral images of AuNPs compared to AuNP-allergen conjugates. d HPLC analysis of allergens before
and after the conjugation with AuNPs
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methods used for characterization corresponded well and
demonstrated that the allergens were successfully conju-
gated to the AuNPs. Accordingly, the DLS measurements
indicated a size increase and zeta potential experiments
determined a marked drop in the negative values when
comparing AuNP-allergen conjugates to the AuNPs alone.
The obtained size increase of the AuNP-allergen conju-
gates did not correlate with the measured hydrodynamic
radius of the allergens, which is due to the fact that DLS
gives the hydrodynamic radius of a perfectly shaped
sphere, which may often lead to an underestimation of the
actual size [51]. Moreover, when investigating the shape of
the allergens from their crystal structures as described by
de Halleux et al. [52] and Kofler et al. [46] it can be seen
that the allergens are not spherical, but rather adopt a cy-
lindrical shape. For quantification of bound allergen we
first employed a theoretical determination. For such esti-
mations the equation previously published by Dell’Ocro et
al. [53] was used. Therefore, the obtained hydrodynamic
radii of the AuNP-allergen conjugates were divided by the
hemispheres of the allergens resulting in the maximal
numbers of binding sites available for each allergen on the
AuNP surface. These calculations showed that DLS data
can be used to determine the available binding sites of
allergens on the AuNPs surface (Table 2). In order to ad-
dress this issue experimentally, an indirect quantification
using RP-HPLC was conducted (Fig. 1d). Single peaks
were detected for the corresponding allergens, which
eluted at 8.6 min (Bet v 1), 8.4 min (Der p 1), and 9.2 min
(Phl p 5), respectively. The peak areas of allergens before
and after the conjugation were compared and the respect-
ive allergen concentrations as well as the number of aller-
gen molecules bound to the AuNPs were calculated for
each preparation (Table 2). It is noteworthy that the results
obtained from both methods matched well, however, for all
further experiments the values obtained by the RP-HPLC-
based indirect quantification method was used [54].
For further characterization of binding properties we
assessed arrangement and orientation, and more specific-
ally the conjugation degree, of the three AuNP-allergen
conjugates [55, 56]. Based on the HPLC results we com-
puted 3D models of AuNP-allergen conjugates (Fig. 2).
Approximate numbers of allergen molecules per AuNP
were adopted from HPLC experiments (Table 2) and set
to 510 (Bet v 1), 380 (Der p 1) and 140 (Phl p 5), illustrat-
ing the amount of AuNP surface covered by allergen
(Fig. 2a). Figure 2b shows two possible orientations of the
three allergens on the AuNP surface. It was assumed that
the orientation selection of allergen molecules relative to
the citrate-coated AuNP surface is primarily controlled by
long-range electrostatic interactions [55, 57, 58]. There-
fore, the chosen orientations minimize contacts between
negative charges and mainly place positively charged
allergen residues on the AuNP surface. In Fig. 2c,
these orientations are shown with accessible allergen
epitopes highlighted in orange. In all three allergens
used the epitopes are available for recognition via IgE.
Impact of the conjugation to AuNPs on the effector
function of allergens
After using various methods for protein corona
characterization, we were confident that AuNP-allergen
conjugates had been formed. Other methods are available,
such as nuclear magnetic resonance, infrared spectroscopy
or circular dichroism, which provide an indication of
structural conformation [56]. The structural integrity of
the allergens used in this study when bound to AuNPs is
important since structural changes can modulate the bio-
logical response. However, the use of these methods by
Calzolai et al. [56] require >400-fold more protein than we
used in our study, making these methods impossible to
use in our experimental conditions. Furthermore, we
consider that allergen-specific cellular responses are
mainly driven by the availability and accessibility of
intact epitopes, which are not limited to a particular
tertiary structure or orientation of the allergen. Therefore,
we performed the BAT, as its clinical relevance as a highly
specific in vitro test system for allergenic activity was just
recently emphasized by a position paper of the European
Academy for Allergy and Clinical Immunology by
Hoffmann et al., in 2015 including the use of BAT to
monitor the patient’s sensitivity to inhalant allergens
over time [59]. The aim was to provide not only an
indication of available epitopes, but also to determine if
the binding of allergens to AuNPs can heighten or reduce
an allergic reaction. This test gives a direct assessment of
allergenic effects in sensitized humans. Although human
basophils are the least abundant population of granulo-
cytes, they play a crucial role in the immediate-type al-
lergic reaction and moreover in allergic inflammation
in general [17, 60, 61]. The exposure of basophils,
from sensitized subjects, to allergens induces cross-linking









AuNP-Bet v 1 conjugates 657 ± 13.3 648 ± 16 490 ± 68.3 516 ± 77
AuNP-Der p 1 conjugates 578 ± 11.7 415 ± 10 530 ± 3.78 379 ± 2
AuNP-Phl p 5 conjugates 365 ± 7.4 224 ± 5 250 ± 24.2 138 ± 13
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of the allergen-specific IgE bound to the cell surface via its
high affinity receptor for IgE (FcεRI), facilitated by the
presence of multiple non-overlapping IgE-binding epi-
topes, resulting in cell degranulation with the release of
preformed mediator substances including histamine, leu-
kotrienes, prostaglandins, and proteases. Upon degranula-
tion, the basophil activation marker CD63, which in
resting basophils is located only in the membrane of the
granules, is expressed at the surface of the basophils, and
this correlates with the released histamine concentration
[62–64]. Donor-to-donor variations can occur, as not only
the amount of allergen-specific IgE in the serum and the
number of FcεRI can vary, but also the IgE repertoire can
be different between different patients. This is expected
for a natural polyclonal IgE response, as for a number
of major allergens a distribution of IgE epitopes across the
entire surface has been shown [62, 65, 66]. Accord-
ingly, a number of conformational, i.e. discontinuous
IgE epitopes of Bet v 1, Der p 1 and Phl p 5 have been
identified by mAB-based, epitope grafting, site-directed
mutagenesis, X-ray crystallography and mimotope ap-
proaches [45, 65, 67–73]. Our 3D model of AuNP-allergen
conjugates hypothesizes coupling of the allergens to the
citrate-coated AuNP surface based on electrostatic inter-
action, which may, in the case of certain examples of
positively charged interaction patches, result in an
alignment on the AuNP surface where the allergens
repetitively display the same epitopes. To investigate
integrity and accessibility of IgE epitopes, experiments
were performed using allergic patients’ whole blood
and stimulation of the basophils with the allergen, the
AuNP-allergen conjugates and the plain AuNPs. No
basophil activation was found when exposed to the
AuNPs alone. The assay was performed for nine
donors allergic to Bet v 1, five donors allergic to Der
p 1, and eight donors allergic to Phl p 5. All donors tested
could be divided into three categories:
i. Donors that did not display a difference in basophil
activation when comparing free versus AuNP-allergen
conjugates, as similar C50 values were observed.
These included examples from each patient subset,
with two, and three examples for Bet v 1 and Phl p 5,
respectively (Figs. 3, 4, 5, Table 3). This infers that in
these donors the allergen-specific IgE antibodies
recognized the same epitopes irrespective of
Fig. 2 3D models of AuNP-allergen conjugates. a Conjugation degree of allergen molecules on a single AuNP. b Preferred orientations arrangements
of allergen molecules as determined by modelling the interaction with the AuNP surface via electrostatic forces (from +5 kT/e in blue to -5 kT/e in
red). c Currently known allergen epitopes (in orange) accessible for biologic reactions, based on modelled data
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whether the allergens were free or conjugated to
the AuNPs.
ii. Donors with lower basophil activation and higher
C50 values upon stimulation with AuNP-allergen
conjugates compared to free allergen, as shown for
Bet v 1 and Phl p 5, with three and one examples,
respectively (Figs. 3, 5, Table 3). In the case of Der p 1,
no reduction in basophil activation was found when
allergen was bound to the AuNPs. This observation
may be explained by an allergen arrangement on the
AuNPs surface, where epitopes are partially hidden or
that these patients’ do not display the specific IgE
against this epitope [62, 74].
iii. Donors which displayed an increase in basophil
activation and thus lower C50 values when cells
were exposed to the AuNP-allergen conjugates
Fig. 3 BAT of allergic patients against Bet v 1. The experiments were performed with 9 donors. The patients’ whole blood was treated with 0.048-50 ng
free Bet v 1 (blue squares) or the respective amount of AuNP-Bet v 1 conjugates (violet triangles). Donor 2, 3, 4 and 7 showed a higher activation upon
stimulation with AuNP-Bet v 1 conjugates, whereas Donor 5, 6 and 9 were less activated by the AuNP-Bet v 1 conjugates. Donor 8 displayed no difference
in the activation pattern. Donor 1 was not used for the determination of the C50 value
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compared to free allergen. This was shown in three
Bet v 1 donors, four Der p 1 donors, and one Phl p 5
donor (Figs. 3, 4, 5, Table 3). With our hypothesized
uniform binding orientation, the conjugated allergens
would align in the same direction enabling more IgE
molecules to crosslink through an increased localized
concentration of the bound allergen [75].
It was furthermore observed that four donors, two for
Bet v 1 (donors 3, 6), one for Der p 1 (donor 1), and one
for Phl p 5 (donor 1), displayed a lower basophil sensi-
tivity which manifested in a lower maximal activation
response (Figs. 3, 4 and 5). Such examples have been de-
scribed before and may be explained by either a lower
total IgE concentration or less allergen-specific IgE
bound to the basophils in those patients compared to
the others [62].
Using the enzymatic function for studying protein-
nanoparticle interactions – the protease activity of Der p 1
Since Der p 1 is known to be a cysteine protease [76],
this intrinsic property was used to investigate the activity
of free Der p 1 versus AuNP-Der p 1 conjugates in an
enzyme activity assay and, secondly, their effect on cell
monolayer tight junctions. For the enzyme activity assay,
the effect of Der p 1 on t-Butyloxycarbonyl-L-glutaminyl-
L-alanyl-L-arginine-4-methylcourmaryl-z-amide (Boc-
Gln-Ala-Arg-AMC) was investigated. Figure 6a displays
the results obtained with 100 ng and 50 ng free Der p 1
compared to 30 ng of conjugated Der p 1. After 20 min
the AMC release was 3-fold higher in case for AuNP-Der
p 1 conjugates compared to 100 ng Der p 1 and 8-fold
higher compared to 50 ng Der p 1. After 40 min the differ-
ence in AMC release was still 2-fold higher than for
100 ng and 5-fold higher than for 50 ng Der p 1 (data not
shown). This observation could be due to the alignment
of Der p 1 on the AuNP surface, which could lead to the
observed higher enzymatic activity.
Additionally, the stability of conjugates, and enzyme
activity, upon storage at 4 °C was investigated. Hence,
the AuNP-Der p 1 conjugates were analyzed after one,
two and three months of storage and compared to the
fresh AuNP-Der p 1 conjugates. In Fig. 6b the difference
in AMC release for AuNP-Der p 1 conjugates is shown;
Fig. 4 BAT of allergic patients against Der p 1. The experiments were performed with 5 donors. The patients’ whole blood was treated with 0.04-50 ng
free Der p 1 (blue squares) or the respective amount of AuNP-Der p 1 conjugates (violet triangles). Donor 2, 3, 4 and 5 were higher activated by the
AuNP-Der p 1 conjugates compared to the allergen alone. Donor 1 was not used for the determination of the C50 value
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with a decrease in AMC release of 1.3-fold, 1.5-fold and
2.2-fold after one, two and three months, respectively,
when compared to the fresh conjugates. These results
gave an insight in the stability of the protein corona of
Der p 1 conjugated to AuNPs. Upon storage in 0.1 M
PBS without an excess of the protein, the proteins either
slowly start to detach from the AuNPs surface or are
subject to a limited degree of degradation.
The protease function of Der p 1 has been reported to
play a functional role in allergic sensitization, as the pro-
tease function may disrupt the epithelial barrier in the
lung [40, 76]. Consequently, such a marked increase in
the enzymatic activity of AuNP-Der p 1 conjugates may
have strong implications for allergic sensitization and
lung pathophysiology upon uptake via inhalation. There-
fore, permeability assays in A549 cells were carried out
Fig. 5 BAT of allergic patients against Phl p 5. The experiments were performed with 8 donors. The patients’ whole blood was treated with
0.078-50 ng free Phl p 5 (blue squares) or the respective amount of AuNP-Phl p 5 conjugates (violet triangles). Donor 8 showed a higher activation
upon stimulation with AuNP-Phl p 5 conjugates, whereas donor 9 was activated to a lesser degree. Donor 4 and 6 did not show a difference in
their activation profile. Donor 1, 2, 3 and 5 were not used for the determination of the C50 value
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to address whether in a more physiological model, com-
pared to the enzyme activity assay, such a high impact of
AuNPs-Der p 1 conjugates could be found. A549 are
cancer cells derived from human type II alveolar epithe-
lial cells, frequently used in investigating effects of
inhaled ENMs, since they can form tight epithelia and
reproduce other features of this cell type, for which pri-
mary cells cannot be obtained. Figure 6c displays the
TEER measurements, as a measure of barrier function,
of A549 cells grown on the membrane of an insert until
forming a tight cell layer. The TEER values of the con-
trol cells on day 4 and 5 did not show significant further
increases, indicating the formation of a tight monolayer
at this time point, as previously described by Schlinkert
et al. [77]. On day 4 the cells were treated for 24 h with
free Der p 1, AuNP-Der p 1 conjugates, which were acti-
vated with 0.1 mM DTT prior to the exposure, 2.5 M
EDTA as a positive control, DTT and plain AuNPs, to
determine if any would alter the TEER values, or left un-
treated (Fig. 6d). The EDTA positive control, and more
noteworthy, both allergen preparations, free Der p 1 and
AuNP-Der p 1 conjugates significantly decreased barrier
function of the lung epithelial cells. Furthermore, when
comparing free Der p 1 to AuNP-Der p1 conjugates,
AuNP-Der p 1 conjugates had a higher impact on the
integrity of the monolayer (P < 0.05). In contrast, neither
0.01 mM DTT (used for activation of the protease
function) nor the AuNPs alone had any effect on
TEER values. The concentration of fluorescein perme-
ating the tight layer was investigated using the same
treatments as described above (Fig. 6e) [78]. These
data were in line with the TEER measurements, with
a significant increase in permeation when cells were
exposed to AuNP-Der p 1 conjugates (P < 0.05) compared
to the same amount of free Der p 1. Both experiments
verified the significant impact on the cell layer when cells
were exposed to AuNP-Der p 1 conjugates, which also
correlated well with the data observed in the enzymatic
activity assay.
Conclusions
In this study we have shown the successful conjugation
of three major outdoor and indoor allergens (Bet v 1,
Der p 1 and Phl p 5) as highly purified and well-
characterized recombinant molecules to 50 nm AuNPs.
The AuNP-allergen conjugates were characterized by
TEM negative staining, DLS and hyperspectral imaging.
All three characterization methods gave correlating re-
sults, namely that the allergens were firmly interacting
with the AuNPs’ surface. Indirect quantification by RP-
HPLC was performed allowing the determination of the
allergen concentration on the AuNPs’ surface. To visualize
the interaction between the allergens and the AuNPs at
the molecular level a 3D model was established based on
crystal and NMR structural information, depicting the ar-
rangement of the allergens on the AuNPs upon electro-
static interaction and the surface exposure of the known
IgE-binding epitopes of the allergens. For providing ex-
perimental evidence for the generated models, the integ-
rity and accessibility of IgE epitopes was determined by
activation assays using human blood basophils derived
from a panel of allergic patients. We observed a high
donor-to-donor variability, depicting similar, higher or
lower basophil responses to free allergen versus the re-
spective amounts of AuNP-allergen conjugates. This led
us to the conclusion that, (i) in case of similar results, the
IgE epitopes of the allergens can be recognized equally
well, (ii) in case of a lower basophil activation, some epi-
topes may become hidden, and the patients’ specific IgE
antibodies are not able to recognize other IgE epitopes
present on the allergens’ surface, and (iii) in the case of
higher basophil activation, an alignment of the allergens
on the AuNPs’ surface takes place which optimally dis-
plays the IgE epitopes relevant for the respective patient.
Table 3 Concentrations of half-maximal basophil activation (C50) of free allergen versus AuNP-allergen conjugates for all donors
tested. In conjugates the given values refer to the amounts of coupled allergen. Donors displaying X were tested but could not be
statistically evaluated
C50 [ng/ml]
Donor Bet v 1 AuNP-Bet v 1 conjugates Der p 1 AuNP-Der p 1 conjugates Phl p 5 AuNP-Phl p 5 conjugates
1 X X X X X X
2 178 1 4 2 X X
3 444 51 186 55 X X
4 52 13 27 1 16 19
5 287 548 58 20 X X
6 78 107 --- --- 1 1
7 48 43 --- --- 29 12
8 2 2 --- --- 65 77
9 12 89 --- --- --- ---
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This would facilitate a more effective IgE receptor crosslink-
ing on the basophils due to a higher localized concentration
of allergens on the AuNPs compared to the free allergen.
AuNP-Der p 1 conjugates were the only AuNP-allergen
conjugates affected by replacement of plasma proteins,
when determining the “hardness” of the protein corona
formed via Western blots as control experiments for the
AuNP-allergen conjugate incubation in plasma during BAT
(Additional File 1: Supplementary material and Additional
File 2: Figure S1). We, furthermore, determined that the en-
zymatic activity of Der p 1 upon binding to AuNPs was
markedly enhanced in a cell free assay, and accordingly,
the conjugates reduced the integrity of a tight cell mono-
layer when compared to free Der p 1. Release of Der p 1
from AuNPs was not fast enough, or to a high enough level,
to abolish an allergy-promoting effect as shown by in-
creased basophil activation. Studies with other allergens are
needed to show how frequent such effects are for allergens
in general.
In summary, this study presents that conjugation of aller-
gens to ENMs can modulate the allergic response. Yet, due
to allergic donor variability, this effect was not consistently
observed. Furthermore the enzymatic activity of the prote-
ase Der p 1 was increased when conjugated to ENMs.
Fig. 6 Determination of protease activity of free Der p 1 versus AuNP-Der p 1 conjugates. a Enzymatic activity assay of 30 ng AuNP-Der p 1
conjugates compared to 50 and 100 ng free Der p 1. b Stability of conjugates addressed by enzymatic activity of 30 ng AuNP-Der p 1 conjugates
upon storage at 4 °C. In conjugates the given values refer to amount of coupled allergen. c TEER measurements of A549 cells to monitor the
formation of a tight cell layer. d TEER measurements of A549 cells exposed to controls, free Der p 1 and AuNP-Der p 1 conjugates (*, p < 0.05).
e Permeation of Fluorescein through a tight monolayer of A549 cells exposed to controls, free Der p 1 and AuNP-Der p 1 conjugates (*, p < 0.05)
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Additional files
Additional file 1 Figure S1. Supplementary material. Control for allergen
corona replacement during basophil activation assays. (DOCX 573 kb)
Additional file 2 Determination of conjugated allergen after the
incubation in human plasma performed by Coomassie-stained SDS-PAGE
(A-C) and Western blots (D-F). (TIF 526 kb)
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